NARI Quote, Financials, Valuation and Earnings

Inspire Medical Systems has a net margin of -11.97% compared to Inari Medical's net margin of 9.1%. Inari Medical's return on equity of -17.68% beat Inspire Medical Systems's return on equity of 5.44%.

Inari Medical has a consensus price target of $64.38, signalling upside risk potential of 2.44%. On the other hand Inspire Medical Systems has an analysts' consensus of $239.60 which suggests that it could grow by 11.23%. Given that Inspire Medical Systems has higher upside potential than Inari Medical, analysts believe Inspire Medical Systems is more attractive than Inari Medical.

Inari Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inspire Medical Systems has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.768%.

Inari Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inari Medical pays -- of its earnings as a dividend. Inspire Medical Systems pays out -- of its earnings as a dividend.

Inari Medical quarterly revenues are $153.4M, which are smaller than Inspire Medical Systems quarterly revenues of $203.2M. Inari Medical's net income of -$18.4M is lower than Inspire Medical Systems's net income of $18.5M. Notably, Inari Medical's price-to-earnings ratio is -- while Inspire Medical Systems's PE ratio is 201.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inari Medical is 6.56x versus 8.57x for Inspire Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -11.97% compared to Inari Medical's net margin of -10.5%. Inari Medical's return on equity of -17.68% beat Myomo's return on equity of -84.04%.

Inari Medical has a consensus price target of $64.38, signalling upside risk potential of 2.44%. On the other hand Myomo has an analysts' consensus of -- which suggests that it could grow by 12.25%. Given that Myomo has higher upside potential than Inari Medical, analysts believe Myomo is more attractive than Inari Medical.

Inari Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.909%.

Inari Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inari Medical pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Inari Medical quarterly revenues are $153.4M, which are larger than Myomo quarterly revenues of $9.2M. Inari Medical's net income of -$18.4M is lower than Myomo's net income of -$966.4K. Notably, Inari Medical's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inari Medical is 6.56x versus 9.98x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Nevro has a net margin of -11.97% compared to Inari Medical's net margin of -15.83%. Inari Medical's return on equity of -17.68% beat Nevro's return on equity of -24.66%.

Inari Medical has a consensus price target of $64.38, signalling upside risk potential of 2.44%. On the other hand Nevro has an analysts' consensus of $5.60 which suggests that it could grow by 47.37%. Given that Nevro has higher upside potential than Inari Medical, analysts believe Nevro is more attractive than Inari Medical.

Inari Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nevro has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.064%.

Inari Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nevro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inari Medical pays -- of its earnings as a dividend. Nevro pays out -- of its earnings as a dividend.

Inari Medical quarterly revenues are $153.4M, which are larger than Nevro quarterly revenues of $96.9M. Inari Medical's net income of -$18.4M is lower than Nevro's net income of -$15.3M. Notably, Inari Medical's price-to-earnings ratio is -- while Nevro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inari Medical is 6.56x versus 0.33x for Nevro. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of -11.97% compared to Inari Medical's net margin of 3.88%. Inari Medical's return on equity of -17.68% beat TransMedics Group's return on equity of 19.83%.

Inari Medical has a consensus price target of $64.38, signalling upside risk potential of 2.44%. On the other hand TransMedics Group has an analysts' consensus of $102.00 which suggests that it could grow by 34.87%. Given that TransMedics Group has higher upside potential than Inari Medical, analysts believe TransMedics Group is more attractive than Inari Medical.

Inari Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TransMedics Group has a beta of 2.124, suggesting its more volatile than the S&P 500 by 112.447%.

Inari Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inari Medical pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Inari Medical quarterly revenues are $153.4M, which are larger than TransMedics Group quarterly revenues of $108.8M. Inari Medical's net income of -$18.4M is lower than TransMedics Group's net income of $4.2M. Notably, Inari Medical's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 80.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inari Medical is 6.56x versus 6.52x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.